IDEAYA Biosciences (IDYA) PE Ratio: History & Chart

IDEAYA Biosciences, Inc.(IDYA)

Biotechnology · South San Francisco, CA

$37.15-0.91 (-2.40%)

Delayed quote: Oct 6, 2026, 12:15 PM EDT

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

South San Francisco, CA

145 employees

www.ideayabio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yujiro S. Hata

View full financials

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
IDEAYA Biosciences, Inc. (IDYA)	$3.53B	N/A	N/A	N/A	N/A
iRhythm Technologies, Inc. (IRTC)vs ›	$3.53B	N/A	N/A	N/A	N/A
Celcuity Inc. (CELC)vs ›	$3.50B	N/A	N/A	N/A	N/A
Regencell Bioscience Holdings Limited (RGC)vs ›	$3.58B	N/A	N/A	N/A	N/A
Pulse Biosciences, Inc. (PLSE)vs ›	$3.43B	N/A	N/A	N/A	N/A
Acadia Pharmaceuticals Inc. (ACAD)vs ›	$3.42B	8.98	12.92	23.68	23.68
CareDx, Inc (CDNA)vs ›	$3.38B	31.55	18.61	17.43	17.43
Parabilis Medicines, Inc. (PBLS)vs ›	$3.34B	N/A	N/A	N/A	N/A
Denali Therapeutics Inc. (DNLI)vs ›	$3.13B	N/A	239.54	239.54	239.54
ICU Medical, Inc. (ICUI)vs ›	$3.98B	134.91	2304.79	2304.79	918.81

NAME

MARKET CAP

PE RATIO

TTM

IDEAYA Biosciences, Inc. (IDYA)

$3.53B

N/A

iRhythm Technologies, Inc. (IRTC)vs ›

$3.53B

N/A

Celcuity Inc. (CELC)vs ›

$3.50B

N/A

Regencell Bioscience Holdings Limited (RGC)vs ›

$3.58B

N/A

Pulse Biosciences, Inc. (PLSE)vs ›

$3.43B

N/A

Acadia Pharmaceuticals Inc. (ACAD)vs ›

$3.42B

8.98

12.92

23.68

CareDx, Inc (CDNA)vs ›

$3.38B

31.55

18.61

17.43

Parabilis Medicines, Inc. (PBLS)vs ›

$3.34B

N/A

Denali Therapeutics Inc. (DNLI)vs ›

$3.13B

N/A

239.54

ICU Medical, Inc. (ICUI)vs ›

$3.98B

134.91

2304.79

918.81

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

IDYA PE Ratio Metrics

IDYA Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics